Lucid Diagnostics LUCD Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Lucid Diagnostics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lucid Diagnostics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lucid Diagnostics's additional paid-in capital?
- Lucid Diagnostics (LUCD) reported additional paid-in capital of $291.66M in Q1 2026.
- How has Lucid Diagnostics's additional paid-in capital changed year-over-year?
- Lucid Diagnostics's additional paid-in capital increased by 62.1% year-over-year, from $179.9M to $291.66M.
- What is the long-term trend for Lucid Diagnostics's additional paid-in capital?
- Over 5 years (2020 to 2025), Lucid Diagnostics's additional paid-in capital has grown at a 279.3% compound annual growth rate (CAGR), from $294K to $230.87M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.